These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23286345)

  • 1. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer.
    Mellor JD; Brown MP; Irving HR; Zalcberg JR; Dobrovic A
    J Hematol Oncol; 2013 Jan; 6():1. PubMed ID: 23286345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
    J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
    Geva R; Vecchione L; Kalogeras KT; Jensen BV; Lenz HJ; Yoshino T; Paez D; Montagut C; Souglakos J; Cappuzzo F; Cervantes A; Frattini M; Fountzilas G; Johansen JS; Høgdall EV; Zhang W; Yang D; Yamazaki K; Nishina T; Papamichael D; Vincenzi B; Macarulla T; Loupakis F; De Schutter J; Spindler KL; Pfeiffer P; Ciardiello F; Piessevaux H; Tejpar S
    Gut; 2015 Jun; 64(6):921-8. PubMed ID: 25011934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
    Ying HQ; Wang F; Chen XL; He BS; Pan YQ; Jie C; Liu X; Cao WJ; Peng HX; Lin K; Wang SK
    Oncotarget; 2015 Sep; 6(29):28071-83. PubMed ID: 26363448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 rituximab IgG1, IgG3, and IgG4 but not IgG2 subclass trigger Ca
    Freitas Monteiro M; Papaserafeim M; Réal A; Puga Yung GL; Seebach JD
    J Leukoc Biol; 2020 Oct; 108(4):1409-1423. PubMed ID: 32620047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.
    Lin TS; Flinn IW; Modali R; Lehman TA; Webb J; Waymer S; Moran ME; Lucas MS; Farag SS; Byrd JC
    Blood; 2005 Jan; 105(1):289-91. PubMed ID: 15217834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population.
    Lejeune J; Piègu B; Gouilleux-Gruart V; Ohresser M; Watier H; Thibault G
    MAbs; 2012; 4(6):784-7. PubMed ID: 23032993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of FCGR2A and FCGR3A variants on CLL outcome.
    Dornan D; Spleiss O; Yeh RF; Duchateau-Nguyen G; Dufour A; Zhi J; Robak T; Moiseev SI; Dmoszynska A; Solal-Celigny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Rossiev VA; Bence-Bruckler I; Geisler CH; Montillo M; Wenger MK; Weisser M
    Blood; 2010 Nov; 116(20):4212-22. PubMed ID: 20705761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
    J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
    Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
    Front Immunol; 2018; 9():2873. PubMed ID: 30574146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J; Gelderblom H; Antonini NF; Tol J; van Krieken JH; van der Straaten T; Punt CJ; Guchelaar HJ
    Eur J Cancer; 2010 Jul; 46(10):1829-34. PubMed ID: 20418097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between the functional FCGR3A F158V and FCGR2A R131H polymorphisms and responsiveness to biologics in rheumatoid arthritis patients: A meta-analysis.
    Lee YH; Song GG
    Int J Rheum Dis; 2023 Jul; 26(7):1295-1304. PubMed ID: 37114884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.
    Hussain K; Hargreaves CE; Rowley TF; Sopp JM; Latham KV; Bhatta P; Sherington J; Cutler RM; Humphreys DP; Glennie MJ; Strefford JC; Cragg MS
    Front Immunol; 2019; 10():390. PubMed ID: 30899264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.
    Lejeune J; Thibault G; Ternant D; Cartron G; Watier H; Ohresser M
    J Clin Oncol; 2008 Nov; 26(33):5489-91; author reply 5491-2. PubMed ID: 18955438
    [No Abstract]   [Full Text] [Related]  

  • 16. Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.
    Erbe AK; Wang W; Gallenberger M; Hank JA; Sondel PM
    Methods Mol Biol; 2016; 1441():43-56. PubMed ID: 27177655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125.
    Wang W; Somers EB; Ross EN; Kline JB; O'Shannessy DJ; Schweizer C; Weil S; Grasso L; Nicolaides NC
    Cytogenet Genome Res; 2017; 152(4):169-179. PubMed ID: 29041009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.
    Erbe AK; Wang W; Goldberg J; Gallenberger M; Kim K; Carmichael L; Hess D; Mendonca EA; Song Y; Hank JA; Cheng SC; Signoretti S; Atkins M; Carlson A; Mier JW; Panka DJ; McDermott DF; Sondel PM
    Clin Cancer Res; 2017 May; 23(9):2159-2168. PubMed ID: 27742794
    [No Abstract]   [Full Text] [Related]  

  • 19. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK; Levy R
    J Clin Oncol; 2003 Nov; 21(21):3940-7. PubMed ID: 12975461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
    Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
    Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.